FDA Might Seek "Intermediate" Action Authority To Enforce Trial Compliance
This article was originally published in The Gray Sheet
Executive SummaryFDA is considering whether to ask Congress for the authority to bring "intermediate" enforcement actions against parties violating clinical trial regs, FDA Office of Regulatory Affairs Director of Enforcement Daniel Michels told the Government Reform/Criminal Justice, Drug Policy and Human Resources Subcommittee.
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.